Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPA1 | O60313 | 1/20 | 0.81 |
| ▸ | EIF5B | O60841 | 1/20 | 0.81 |
| ▸ | MET | P08581 | 1/20 | 0.81 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.81 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.37 |
| ▸ | IDO1 | P14902 | 3/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10057611 | 1.00 | OPA1 (0.81) | OPA1EIF5BMETHMOX2HTR2A | |
| Tivantinib SCHEMBL44944 | 0.89 | OPA1 (1.00) | OPA1EIF5BMETHMOX2HTR2A | |
| Tivantinib SCHEMBL1395795 | 0.89 | OPA1 (1.00) | OPA1EIF5BMETHMOX2HTR2A | |
| Tivantinib SCHEMBL29355700 | 0.89 | OPA1 (1.00) | OPA1EIF5BMETHMOX2HTR2A | |
| Tivantinib SCHEMBL2036414 | 0.89 | OPA1 (1.00) | OPA1EIF5BMETHMOX2HTR2A | |
| Tivantinib SCHEMBL45306 | 0.89 | OPA1 (1.00) | OPA1EIF5BMETHMOX2HTR2A | |
| Tivantinib SCHEMBL14865187 | 0.89 | OPA1 (1.00) | OPA1EIF5BMETHMOX2HTR2A | |
| Tivantinib SCHEMBL44902 | 0.89 | OPA1 (1.00) | OPA1EIF5BMETHMOX2HTR2A | |
| Tivantinib SCHEMBL224883 | 0.89 | OPA1 (1.00) | OPA1EIF5BMETHMOX2HTR2A | |
| Tivantinib SCHEMBL12043258 | 0.89 | OPA1 (1.00) | OPA1EIF5BMETHMOX2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9642847-B2 | Combinational compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160355515-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. | 2016-12-08 | — | — | US | disclosed |
| US-9447088-B2 | Compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20150328208-A1 | COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. | 2015-11-19 | — | — | US | disclosed |
| US-20150297604-A1 | Combination Products with Tyrosine Kinase Inhibitors and their Use | NOVARTIS AG (CH) | 2015-10-22 | — | — | US | disclosed |
| US-9000005-B2 | Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same | ARQULE, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20150051210-A1 | Tyrosine Kinase Inhibitor Combinations and their Use | NOVARTIS AG (CH) | 2015-02-19 | — | — | US | disclosed |
| US-20140200199-A1 | Compositions and Methods for Treatment of Cancer | ARQULE, INC. | 2014-07-17 | — | — | US | disclosed |
| US-8754078-B2 | Compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130281699-A1 | Highly Pure Pyrroloquinolinyl-Pyrrole-2,5-Dione and Pyrroloquinolinyl-Pyrrolidine-2,5-Dione and Methods of Preparing Same | ARQULE, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-8470786-B2 | Pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same | ARQULE, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20130150310-A1 | Compositions and Methods for Treatment of Cancer | ARQULE, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20120165278-A1 | Pyrroloquinolinyl-Pyrrolidine-2,5-Dione Compositions And Methods For Preparing And Using Same | ARQULE, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120052062-A1 | Methods for Treatment of Non-Small Cell Lung Cancer | ARQULE, INC. (US) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328208-A1 | COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | TP53, MKI67, POLI | OPA1 218/4885EIF5B 490/4885MET 1267/4885 |
| US-20130281699-A1 | Highly Pure Pyrroloquinolinyl-Pyrrole-2,5-Dione and Pyrroloquinolinyl-Pyrrolidine-2,5-Dione and Methods of Preparing Same | DHPS, QDPR, IDO1 | OPA1 100/4885EIF5B 1594/4885MET 4773/4885 |
| US-20140200199-A1 | Compositions and Methods for Treatment of Cancer | MKI67, NUP205, TP53 | OPA1 88/4885EIF5B 402/4885MET 2895/4885 |
| US-20160355515-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | MKI67, NUP205, TP53 | OPA1 88/4885EIF5B 402/4885MET 2895/4885 |
| US-20150051210-A1 | Tyrosine Kinase Inhibitor Combinations and their Use | MET, FGFR3, FGFR1 | OPA1 4868/4885EIF5B 2641/4885MET 1/4885 |
| US-20120165278-A1 | Pyrroloquinolinyl-Pyrrolidine-2,5-Dione Compositions And Methods For Preparing And Using Same | DHPS, PDCD5, DPYD | OPA1 63/4885EIF5B 389/4885MET 4439/4885 |
| US-20150297604-A1 | Combination Products with Tyrosine Kinase Inhibitors and their Use | EGFR, ERBB2, ERBB3 | OPA1 4869/4885EIF5B 668/4885MET 4/4885 |
| US-20120052062-A1 | Methods for Treatment of Non-Small Cell Lung Cancer | EGFR, DCK, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | OPA1 3004/4885EIF5B 887/4885MET 6/4885 |
| US-20130150310-A1 | Compositions and Methods for Treatment of Cancer | MKI67, NUP205, TP53 | OPA1 88/4885EIF5B 402/4885MET 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.